Gilead Sciences’ (GILD) Buy Rating Reaffirmed at Truist Financial

Gilead Sciences’ (GILD) Buy Rating Reaffirmed at Truist Financial

Truist Financial reaffirmed their buy rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a report issued on Monday morning,Benzinga reports. Truist Financial currently has a $145.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $127.00. A number of other brokerages also recently commented on GILD. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a researc…

Zhang Financial LLC Lowers Stock Holdings in Gilead Sciences, Inc. $GILD

Zhang Financial LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 50.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,944 shares of the biopharmaceutical company’s stock after selling 1,965 shares during the period. Zhang Financial LLC’s holdings in Gilead Sciences […]